A patient-facing explanation of the muscle-brain axis — how skeletal muscle signals to the brain during exercise, which effects have human evidence behind them, and what remains extrapolated from preclinical work for APOE ε4 carriers specifically.
The mechanistic basis of exercise-induced neuroprotection — myokine signaling, neurotrophic pathways, and metabolic effects — with explicit attention to where genotype-stratified randomized data exist and where they remain absent.
Two opposing pharmacological hypotheses have been advanced for APOE4 carriers: wake-promoting agents such as armodafinil, versus dual orexin receptor antagonists. This review examines the mechanistic rationale and the human evidence behind each, and why only one is currently supportable.
Amen’s daily reader recommends a lifestyle framework and a nine-supplement regimen in the same register. Only one survives comparison with the randomized evidence. US POINTER (n=2,111) found structured lifestyle intervention worked regardless of ε4 status; PreventE4 (n=365, 24 months) raised CSF DHA 17% with no cognitive or volumetric benefit. What a clinician should endorse, and what the reader cannot distinguish from within the text, is the appraisal.
The revised criteria redefine Alzheimer’s disease as a biological entity identified by biomarkers rather than by symptoms alone. This review explains the biological staging framework, what it changes for asymptomatic carriers, and the clinical controversies it has generated.
Cardiovascular risk factors are among the most consistently modifiable contributors to dementia risk, but the magnitude of benefit is not uniform across APOE genotypes. A physician’s guide to lipid management, blood pressure, and vascular optimization with the genotype-stratified evidence foregrounded.
Sleep is among the few modifiable factors with a direct mechanistic link to Alzheimer’s pathology, including glymphatic clearance of amyloid. This review covers sleep architecture, obstructive sleep apnea, and the genotype-stratified evidence most relevant to APOE ε4 carriers.
Clinical Case Vignette — Anti-Amyloid Therapy ARIA-E After Donanemab in an APOE ε4 Carrier: Risk Stratification, Management, and Rechallenge Considerations…
Anti-Amyloid Therapy Candidacy in APOE ε4 Heterozygotes with Prior Microhemorrhages | ApoE4 Insights Clinical Content — For Licensed Healthcare Professionals…
Evidence-Based Review APOE ε4 · Pre-Symptomatic 2026 · Peer-Reviewed Synthesis APOE ε4 Carrier: Pre-SymptomaticEvidence-Based Management What to do — and…